Zobrazeno 1 - 10
of 1 140
pro vyhledávání: '"L. Geiger"'
Autor:
John L. Geiger, Howard Suber
What they won't teach you in film school: This expertly written reference guide breaks down copyright laws for screenwriters. Inspired by Strunk & White's The Elements of Style, this elegant, short reference is the perfect guide for screenwriters
Autor:
Wei Zheng, Jing Sun, Jeffrey Weber, Manish R Patel, Brandon Coder, Igor Feldman, Justin F Gainor, Jessica L Geiger, Martin Gutierrez, Joshua Frederick, Celine Robert-Tissot, Robert Meehan, Jack Pollard, Lakshmi Srinivasan, Michelle Brown, Kedar Kirtane, Julie E Bauman, Praveen Aanur, Jeffrey M Clarke, Ricklie A Julian, Aaron J Scott, Moomal Tasneem, Lauren Gerbereux, Andressa Laino, Peijie Hou, Vasudha Sehgal, Hikmat N Daghestani, Howard A Burris
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/ee729db4f6cb4ebfac2f821adca02921
Publikováno v:
Royal Society Open Science, Vol 9, Iss 7 (2022)
The rivers of southeastern Australia host a species complex within the carp gudgeon genus Hypseleotris that includes parental species and hemiclonal hybrid lineages. These hemiclones can be difficult to distinguish from their parent taxa, making deli
Externí odkaz:
https://doaj.org/article/57867f7c402d44908ece866739837f64
Autor:
Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku, Joseph Scharpf, Brandon L. Prendes, Nikhil P. Joshi, Jimmy J. Caudell, Farzan Siddiqui, Sandro V. Porceddu, Nancy Lee, Larisa Schwartzman, Shlomo A. Koyfman, David J. Adelstein, Jessica L. Geiger
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2409-2419 (2021)
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, con
Externí odkaz:
https://doaj.org/article/6936c992016a4b2ca14823b8e16083d3
Autor:
Jessica L. Geiger, Elizabeth D. Cedars, Yan Zang, Daniel P. Normolle, Hua Li, Jennifer R. Grandis, Sara Centuori, Daniel E. Johnson, Julie E. Bauman
Publikováno v:
Laryngoscope Investigative Otolaryngology, Vol 6, Iss 1, Pp 116-121 (2021)
Abstract Objective Buccal cells are an ideal surrogate tissue for studying biologic effects of carcinogens or drugs, however inherent fragility and salivary RNAses limit RNA yield. We conducted healthy volunteer trials to optimize collection conditio
Externí odkaz:
https://doaj.org/article/18cd0ea96d0143c78ff8b8479ee88aa9
Autor:
Rebecca Finger‐Higgens, Tara B. B. Bishop, Jayne Belnap, Erika L. Geiger, Edmund E. Grote, David L. Hoover, Sasha C. Reed, Michael C. Duniway
Publikováno v:
Global Change Biology. 29:3364-3377
Autor:
Logan Roof, Jessica L Geiger
Publikováno v:
Cancer Management and Research. 15:343-350
Autor:
Shannon S. Wu, Nikhil Joshi, Jonathan Sharrett, Sanjay Rao, Akeesha Shah, Joseph Scharpf, Brian Burkey, Eric D. Lamarre, Brandon Prendes, Allan Siperstein, Joyce Shin, Eren Berber, Judy Jin, Vikram Krishnamurthi, Christian Nasr, Li Hong, David S. Buchberger, Neil Woody, Shlomo A. Koyfman, Jessica L. Geiger
Publikováno v:
JAMA otolaryngology-- headneck surgery.
ImportanceTall cell morphology (TCM) is a rare and aggressive variant of papillary thyroid carcinoma (PTC) that has been associated with poor outcomes; however, the risk factors for worse survival are not well characterized.ObjectiveTo identify progn
Autor:
Dirk Schadendorf, Ralf Gutzmer, Thomas Eigentler, Israel Lowy, Vladimir Jankovic, Elizabeth Stankevich, Anna C Pavlick, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Brett G M Hughes, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Brian Stein, Jessica L Geiger, Murad Alam, Emmanuel Okoye, Melissa Mathias, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and th
Externí odkaz:
https://doaj.org/article/a6c7cd3cc4a44c238d9eeebc62a5df0f
Autor:
Aimee C. Talleur, Amr Qudeimat, Jean-Yves Métais, Deanna Langfitt, Ewelina Mamcarz, Jeremy Chase Crawford, Sujuan Huang, Cheng Cheng, Caitlin Hurley, Renee Madden, Akshay Sharma, Ali Suliman, Ashok Srinivasan, M. Paulina Velasquez, Esther A. Obeng, Catherine Willis, Salem Akel, Seth E. Karol, Hiroto Inaba, Allison Bragg, Wenting Zheng, Sheng M. Zhou, Sarah Schell, MaCal Tuggle-Brown, David Cullins, Sagar L Patil, Ying Li, Paul G. Thomas, Caitlin Zebley, Benjamin Youngblood, Ching-Hon Pui, Timothy Lockey, Terrence L. Geiger, Michael M. Meagher, Brandon M. Triplett, Stephen Gottschalk
Publikováno v:
Blood Advances. 6:5737-5749
T cells expressing CD19-specific chimeric antigen receptors (CD19-CARs) have potent antileukemia activity in pediatric and adult patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL). However, not all patients achieve a